Pexidartinib

Pexidartinib
Clinical data
Trade names	Turalio
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 5-[(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-{[6-(trifluoromethyl)-3-pyridinyl]methyl}-2-pyridinamine;
CAS Number	1029044-16-3;
PubChem CID	25151352;
IUPHAR/BPS	8710;
DrugBank	DB12978;
ChemSpider	35308322;
UNII	6783M2LV5X;
KEGG	D11270;
ChEBI	CHEBI:145373;
ChEMBL	ChEMBL3813873;
Chemical and physical data
Formula	C20H15ClF3N5
Molar mass	417.82 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES ClC=1C=C2C(=NC1)NC=C2CC=2C=CC(=NC2)NCC=2C=NC(=CC2)C(F)(F)F;
	InChI InChI=1S/C20H15ClF3N5/c21-15-6-16-14(10-28-19(16)29-11-15)5-12-2-4-18(26-7-12)27-9-13-1-3-17(25-8-13)20(22,23)24/h1-4,6-8,10-11H,5,9H2,(H,26,27)(H,28,29); Key:JGWRKYUXBBNENE-UHFFFAOYSA-N;

Pexidartinib (trade name Turalio; development code name PLX-3397) is a CSF1R antagonist drug created by Plexxikon[1][2]

On 2 August 2019 it was approved by U.S. FDA for treatment of Giant-cell tumor of the tendon sheath (GC-TS).[3][4]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.